RxDoctor Payments Data

Roehl Pena, MD

Internal Medicine · Las Vegas, NVNPI 1770520306

Payments from drug & device makers

$4,185in general payments, 2019–2025

Across 225 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$731
  • Novo Nordisk$416
  • Johnson & Johnson$408
  • Lilly USA, LLC$380
  • Amgen$377
  • Pfizer$294
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$4,05597%
  • Education$1303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,185 in reported general payments places this provider in the 85th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$98,542
Medicare patients
260
Services billed
972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide202$285,079
TrulicityDulaglutide101$155,665
JardianceEmpagliflozin89$109,367
EliquisApixaban49$72,280
FarxigaDapagliflozin Propanediol54$55,043
JanuviaSitagliptin Phosphate33$41,831
MounjaroTirzepatide15$19,426
RexultiBrexpiprazole11$18,456
XareltoRivaroxaban11$16,425
Tresiba Flextouch U-200Insulin Degludec14$14,842
Repatha SyringeEvolocumab17$12,833
TradjentaLinagliptin11$11,582
VascepaIcosapent Ethyl11$11,225
PremarinEstrogens, Conjugated13$7,828
DapagliflozinDapagliflozin Propanediol12$6,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$416$285,079202 claims
Lilly USA, LLCTrulicity, Mounjaro$380$175,091116 claims
Boehringer IngelheimJardiance, Tradjenta$96$120,949100 claims
PfizerEliquis, Premarin$294$80,10862 claims
AstraZenecaFarxiga, Symbicort$731$60,55572 claims
MerckJanuvia$143$41,83133 claims
Otsuka America Pharmaceutical, Inc.Rexulti$39$18,45611 claims
Johnson & JohnsonXarelto$408$16,42511 claims
AbbVieSynthroid$143$2,39142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →